Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof5TWM2OD1yLkCyPFA3KM7:TR?= NH;CTGpUSU6JRWK=
KS-1 NXXCdItOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e1RmlEPTB;MD6wN|g{PSEQvF2= Mn73V2FPT0WU
TE-11 MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe4WGxKSzVyPUCuNFc5OjJizszN M2XTZnNCVkeHUh?=
EW-1 M3zUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i3WmlEPTB;MD6wPFU5PSEQvF2= MlLVV2FPT0WU
HMV-II MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;YWWlEPTB;MD6wPFg1PiEQvF2= Mn;CV2FPT0WU
COLO-205 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPyZotkUUN3ME2wMlExPDV2IN88US=> NHjEWWRUSU6JRWK=
ES1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTxRW5KSzVyPUCuNVA3QTZizszN MV7TRW5ITVJ?
GDM-1 NFfDSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nMXGlEPTB;MD6xN|Y4OiEQvF2= NHPmTYFUSU6JRWK=
ML-2 M3XQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj0TWM2OD1yLkG1PFk3KM7:TR?= M{PZc3NCVkeHUh?=
Saos-2 NH7RUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknXTWM2OD1yLkG2OVI3KM7:TR?= NIDXWY5USU6JRWK=
NCI-H1355 NIOxV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G2dWlEPTB;MD6xPFE{PSEQvF2= NE\hTVJUSU6JRWK=
G-401 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC4TWM2OD1yLkG4NlMh|ryP Ml\WV2FPT0WU
EW-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnnbW9KUUN3ME2wMlE5Pzd5IN88US=> NHLuN4RUSU6JRWK=
EW-7 NWLOTJI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13sZ2lEPTB;MD6xPFg5OSEQvF2= NHjxXFVUSU6JRWK=
NCI-H727 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\TbGlEPTB;MD6xPVc6PCEQvF2= Mmq4V2FPT0WU
LCLC-97TM1 MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMkC5OVUh|ryP M4DrcnNCVkeHUh?=
NCI-H650 NXrVWIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMkGzPFQh|ryP MXXTRW5ITVJ?
NCI-H2122 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPrTWM2OD1yLkKzNlk6KM7:TR?= M3zoPXNCVkeHUh?=
SK-N-DZ NFrQNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC3NVBnUUN3ME2wMlI{Pjl6IN88US=> NXXQV49qW0GQR1XS
HT-29 NFjlTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLzdY1KSzVyPUCuNlQzPDhizszN NFLUUZFUSU6JRWK=
LB771-HNC NELhdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nWemlEPTB;MD6yOVkyPSEQvF2= MYLTRW5ITVJ?
HT-144 NHPiRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq4NnJ{UUN3ME2wMlI3OTlzIN88US=> NFvQc5VUSU6JRWK=
LAN-6 MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\ZTWM2OD1yLkK2N|Q5KM7:TR?= MUjTRW5ITVJ?
EW-18 NVS5fVBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\FTmlEPTB;MD6yO|AxOSEQvF2= Ml;OV2FPT0WU
LS-1034 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;oV2tKSzVyPUCuNlcyOzJizszN M3TFWnNCVkeHUh?=
EW-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPvWHJKSzVyPUCuNlg1OzJizszN M1rIc3NCVkeHUh?=
SNU-C1 M4DH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrTVZp6UUN3ME2wMlI6OzF|IN88US=> MmiyV2FPT0WU
RS4-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjmbHVnUUN3ME2wMlM{PzV6IN88US=> NIfTS3VUSU6JRWK=
ES4 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPkTWM2OD1yLkSxNFM5KM7:TR?= NWrWd3Y5W0GQR1XS
COLO-320-HSR MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW1TWM2OD1yLkSxN|Y5KM7:TR?= NX;lTWpFW0GQR1XS
NB10 NWC1Z402T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvMN4IzUUN3ME2wMlQ2PDN5IN88US=> NH3hUItUSU6JRWK=
BFTC-905 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rKOWlEPTB;MD60Olc2QCEQvF2= MUPTRW5ITVJ?
A375 MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnBTWM2OD1yLkS3OlE4KM7:TR?= M1TQPXNCVkeHUh?=
SJRH30 NWr2cG83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj1OJA6UUN3ME2wMlUxQDJ{IN88US=> NVz0eIhVW0GQR1XS
NOS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNUKyOlch|ryP MUnTRW5ITVJ?
SIG-M5 M2PJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPCO2VKSzVyPUCuOVM2PTdizszN MV3TRW5ITVJ?
DOK NF;nUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzjTWM2OD1yLkW1OkDPxE1? NYfqeok5W0GQR1XS
NB69 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwNUiyOVch|ryP MUTTRW5ITVJ?
SK-NEP-1 NGTrSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjFTWM2OD1yLk[wNlM3KM7:TR?= NHfSVm1USU6JRWK=
SK-MM-2 NETscWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnWWHRIUUN3ME2wMlY2PDlzIN88US=> Ml7zV2FPT0WU
NCI-H358 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEexN3NKSzVyPUCuOlcxQDJizszN MVnTRW5ITVJ?
RH-1 NG[xPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfqTWM2OD1yLke0PFU6KM7:TR?= MX;TRW5ITVJ?
NH-12 NXjhfo92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[4WIhKSzVyPUCuO|YxPDZizszN M3nWSXNCVkeHUh?=
TE-12 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwN{[0PFYh|ryP NUDSfJAyW0GQR1XS
COLO-668 NXTHfox{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fGe2lEPTB;MD64OFY3PiEQvF2= M1LxXHNCVkeHUh?=
PANC-08-13 M{\1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LlOmlEPTB;MD64OlM4PyEQvF2= NGS0VXFUSU6JRWK=
HCC2998 NF\vNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwOEiyOlMh|ryP MWjTRW5ITVJ?
ABC-1 NHHmeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfQTWM2OD1yLkmwN|UzKM7:TR?= NX33Xm9IW0GQR1XS
ES6 M{Lv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwOUGwOlYh|ryP NX\pXm9WW0GQR1XS
SNU-387 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXoblhsUUN3ME2wMlk6Ozl|IN88US=> MWrTRW5ITVJ?
CMK M1PROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwOUm5Nlkh|ryP MVHTRW5ITVJ?
SJSA-1 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\5TWM2OD1zLkCzOlU{KM7:TR?= NYP3PFZtW0GQR1XS
SIMA M2LMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPUR4hTUUN3ME2xMlA3QDJ3IN88US=> MWrTRW5ITVJ?
ES3 NYrqbIhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwMUKyPVch|ryP NWi5S403W0GQR1XS
IGROV-1 M1jCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW1TWM2OD1zLkG1OFQ1KM7:TR?= M2nyTXNCVkeHUh?=
MEL-JUSO M1LSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwMUW3OVkh|ryP M3jJd3NCVkeHUh?=
T84 M1m1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe5PG5KSzVyPUGuNlA6OTRizszN M2i4b3NCVkeHUh?=
CAL-85-1 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G1WmlEPTB;MT6yN|E{QCEQvF2= NFPiTXdUSU6JRWK=
RD MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfaNIVKSzVyPUGuNlY1PTVizszN NH3mcZNUSU6JRWK=
TE-8 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrITWM2OD1zLkOxOFYzKM7:TR?= MYHTRW5ITVJ?
L-363 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\OVWlEPTB;MT6zOFIxQCEQvF2= MWHTRW5ITVJ?
EKVX NFT4[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjxfWFKSzVyPUGuN|Q2PjhizszN MWTTRW5ITVJ?
SK-MEL-3 M2HWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILoeplKSzVyPUGuOFg2PTZizszN NW\HdlU1W0GQR1XS
TGBC24TKB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInxNm9KSzVyPUGuOVAyQTNizszN MmjpV2FPT0WU
NCI-H1770 M3j0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHmTWM2OD1zLkWxNVE{KM7:TR?= NFXmSHdUSU6JRWK=
HuH-7 NHnKclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX63fGhEUUN3ME2xMlYxODl6IN88US=> M4DVSXNCVkeHUh?=
HL-60 NV24WY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\pdWlEPTB;MT62OlkzQCEQvF2= MYnTRW5ITVJ?
TE-1 NETxdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPBcoxLUUN3ME2xMlcxQTR3IN88US=> NInucnFUSU6JRWK=
LC-2-ad NGDlRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jSdGlEPTB;MT63N|g5PyEQvF2= NVXybYpXW0GQR1XS
LB647-SCLC MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXPTWM2OD1zLke2OVg{KM7:TR?= MXfTRW5ITVJ?
NCI-H2171 NF;1RYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7tPHpKSzVyPUGuO|c4OTZizszN MUfTRW5ITVJ?
SK-PN-DW NHPpOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwOUGyPVgh|ryP MoPQV2FPT0WU
MC-IXC NEniSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHZTWM2OD1zLkm4PVgh|ryP NGn1[ZZUSU6JRWK=
LS-513 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq5TWM2OD1{LkC1N|A2KM7:TR?= Mk\pV2FPT0WU
EW-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwMEm4OFQh|ryP MmXHV2FPT0WU
OPM-2 M3KxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzMOHdKSzVyPUKuNVAzKM7:TR?= NYe0PJBsW0GQR1XS
LP-1 NInuUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z5ZmlEPTB;Mj6yOVgxPyEQvF2= NGr0PJBUSU6JRWK=
LU-134-A NXHMd2d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TLR2lEPTB;Mj6yO|ch|ryP MWrTRW5ITVJ?
CP66-MEL M2jUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlKyTWM2OD1{LkK5NFE1KM7:TR?= MUPTRW5ITVJ?
HCC1143 NEHQUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkezTWM2OD1{LkS1N|Y5KM7:TR?= NITs[5RUSU6JRWK=
LOXIMVI MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3znWWlEPTB;Mj62NFIyKM7:TR?= MkK1V2FPT0WU
TE-10 NFniV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwN{C4N|gh|ryP MUfTRW5ITVJ?
NCI-H1882 NXHtOmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q3e2lEPTB;Mj63OVIzPyEQvF2= MkjvV2FPT0WU
CHP-126 M{nWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJwN{[zNVch|ryP MX7TRW5ITVJ?
NCI-H1623 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTtcGR2UUN3ME2yMlkzODJ2IN88US=> NX:2SnJ3W0GQR1XS
GB-1 NH3XbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV24bZkyUUN3ME2yMlk{PDB2IN88US=> M4PLe3NCVkeHUh?=
RCC10RGB M1K1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrYZmVKSzVyPUKuPVUzQDFizszN M37DUHNCVkeHUh?=
NCI-H2141 NFLXV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\SfYdKSzVyPUKuPVY5QTZizszN M2S4RXNCVkeHUh?=
GI-ME-N NYjmSo01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L6c2lEPTB;Mz6wNFU3PSEQvF2= NW\lc|VkW0GQR1XS
NCI-H526 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTLb41KSzVyPUOuNFQxQDVizszN Mn;tV2FPT0WU
NCI-H747 NYTvV2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3obIp5UUN3ME2zMlA1QTl{IN88US=> NXm2XVNEW0GQR1XS
SNU-423 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTNwMkCzNVMh|ryP M{TRZ3NCVkeHUh?=
A427 M3\FTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELETHNKSzVyPUOuNlU3QTlizszN MVjTRW5ITVJ?
CAL-12T M4jjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNwNEC3NVMh|ryP MWLTRW5ITVJ?
LU-99A MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:2[YY3UUN3ME2zMlQ4OTB3IN88US=> NV3SZWUyW0GQR1XS
MS-1 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOzUnBFUUN3ME2zMlU{PDJ7IN88US=> M3jEbnNCVkeHUh?=
SK-LU-1 NHr6[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPLTWM2OD1|Lke2Nlk2KM7:TR?= NEPKNlFUSU6JRWK=
SW837 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi4VGlKSzVyPUOuO|Y{OzNizszN MWrTRW5ITVJ?
ES8 NVHTRlZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTNwOEO4O|ch|ryP Mn6yV2FPT0WU
MZ2-MEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX2TWM2OD1|LkmyNFg3KM7:TR?= NXXrcnRxW0GQR1XS
TGW MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rLTWlEPTB;ND6wNVMyOSEQvF2= M4Dm[nNCVkeHUh?=
GP5d MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLhTWM2OD12LkC1N|YzKM7:TR?= MXLTRW5ITVJ?
BB49-HNC Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\MTWM2OD12LkG1NlE{KM7:TR?= MUfTRW5ITVJ?
NB13 NHnlXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRwMk[4PFch|ryP NWPPXFFJW0GQR1XS
NTERA-S-cl-D1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOzRYhOUUN3ME20MlI5PjF3IN88US=> NH\5PFRUSU6JRWK=
NCI-H1648 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLYNIJKSzVyPUSuNlk5OTlizszN M4jXXHNCVkeHUh?=
LCLC-103H NUnLfYdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHYd5E2UUN3ME20MlMzOTl3IN88US=> M3rjOnNCVkeHUh?=
LS-411N NH;IcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nrXGlEPTB;ND60OFg5PSEQvF2= Mn3kV2FPT0WU
NCI-H1092 NXnOe29UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTRwNEW2PFch|ryP MUHTRW5ITVJ?
PANC-10-05 M4X4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTRwNkm4OEDPxE1? NEP1OHJUSU6JRWK=
DK-MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3NRpdKSzVyPUSuPFA6OzNizszN NYrnd2k3W0GQR1XS
OVCAR-5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofyTWM2OD12LkixNlI3KM7:TR?= M4DhbXNCVkeHUh?=
CAL-39 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwOEe2O{DPxE1? NGS2TllUSU6JRWK=
TE-441-T NIKydlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Lmd2lEPTB;ND65NFU{PyEQvF2= NFezc5JUSU6JRWK=
MOLT-16 M3H3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrWTWM2OD12Lkm1NlU{KM7:TR?= M4D6UXNCVkeHUh?=
MCF7 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fWeGlEPTB;NT6xOFUyPyEQvF2= MWLTRW5ITVJ?
CAPAN-1 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TSSGlEPTB;NT6yOVcxPyEQvF2= M3;nNHNCVkeHUh?=
PSN1 NYTsWnp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe1NHdHUUN3ME21MlI4OjN3IN88US=> NGHpdYNUSU6JRWK=
NCI-H292 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DjUGlEPTB;NT6zNFA1PCEQvF2= M1;qZXNCVkeHUh?=
CPC-N MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTLTWM2OD13LkO5OFE6KM7:TR?= Mor3V2FPT0WU
DoTc2-4510 NI\IOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\INWlEPTB;NT60OVM4OSEQvF2= Mln4V2FPT0WU
LB1047-RCC Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rOeGlEPTB;NT61OVk{OyEQvF2= M2PXUXNCVkeHUh?=
MHH-ES-1 M{fJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDlTWM2OD13LkW5PVA4KM7:TR?= MorZV2FPT0WU
NMC-G1 MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOwbG5QUUN3ME21MlcxOjJ5IN88US=> NX7JXmNTW0GQR1XS
SW1710 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW0U4pKSzVyPUWuO|Q4PTFizszN NGTJdWJUSU6JRWK=
YAPC M2nVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;iTWM2OD13Lke2NlAyKM7:TR?= NH3telZUSU6JRWK=
22RV1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwOECwNVkh|ryP MVzTRW5ITVJ?
COLO-679 M1\wU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTUXoNkUUN3ME21Mlg5QTR6IN88US=> NGX1SZZUSU6JRWK=
TCCSUP NFy0PGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVwOUOyOVkh|ryP MX\TRW5ITVJ?
C2BBe1 NFfwXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLhTWM2OD13LkmzPVch|ryP NW\oPFZ4W0GQR1XS
TE-15 M1jFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml22TWM2OD14LkC2OlA2KM7:TR?= MlOyV2FPT0WU
SCLC-21H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXhemFKSzVyPU[uNVA5PDNizszN MVzTRW5ITVJ?
EoL-1-cell NV;3dnVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j0Z2lEPTB;Nj6xOlU3OyEQvF2= MnT6V2FPT0WU
NKM-1 NHTYdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvWTWM2OD14LkG2O|Eh|ryP MULTRW5ITVJ?
NCI-H1304 M2DRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTZwMke0Nlgh|ryP MnW2V2FPT0WU
NB6 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuxSJhKSzVyPU[uNlk3OjJizszN MXXTRW5ITVJ?
NALM-6 NG\LRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K2NGlEPTB;Nj6zN|I{KM7:TR?= M{DCdXNCVkeHUh?=
NCI-H522 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTZwM{OzNFYh|ryP NHrGeGhUSU6JRWK=
MV-4-11 M{jj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe5Wm9KSzVyPU[uN|cxPzlizszN NVO1UIFTW0GQR1XS
LB2241-RCC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXEUlliUUN3ME22MlM5PjZ5IN88US=> MWTTRW5ITVJ?
NCI-H1417 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTzTWM2OD14LkSwPFQ4KM7:TR?= NH7WeYVUSU6JRWK=
HT-1197 NInvXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zWfGlEPTB;Nj61O|EzOiEQvF2= MkK1V2FPT0WU
P30-OHK M2rnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn1ZYZmUUN3ME22MlYzPzdizszN MkL2V2FPT0WU
ALL-PO NYrCd|JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\a[4pzUUN3ME22MlcyQTF4IN88US=> M1y0VHNCVkeHUh?=
OVCAR-4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn1dJRKSzVyPU[uO|U1ODVizszN M2DRTXNCVkeHUh?=
HCC2157 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTZwN{e0O|Uh|ryP NETVWlBUSU6JRWK=
NCI-H838 M13HeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZwOU[0PUDPxE1? MX3TRW5ITVJ?
NCI-H1299 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnaSJJLUUN3ME22Mlk4ODlizszN M3vzSXNCVkeHUh?=
SW954 NHvDZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHoXXc3UUN3ME23MlIxODZ6IN88US=> M1LpU3NCVkeHUh?=
NCI-H441 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XQVGlEPTB;Nz6zOFA3PSEQvF2= NWraUHBjW0GQR1XS
SK-MEL-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TIUmlEPTB;Nz60PFM4OyEQvF2= NVjMOWhjW0GQR1XS
KARPAS-45 M4nLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj1XFVKSzVyPUeuOlU6OjlizszN MXjTRW5ITVJ?
CAL-54 M1fsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG4dmZKSzVyPUeuPFI6PzdizszN NFjtWmtUSU6JRWK=
KYSE-180 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LyUWlEPTB;Nz64PFk1OSEQvF2= MUjTRW5ITVJ?
NCI-H187 M4DZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC3TWM2OD15Lkm1PVQ4KM7:TR?= MXHTRW5ITVJ?
RT-112 NX;uNIpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf4eWxtUUN3ME24MlA6Pjd5IN88US=> Mke1V2FPT0WU
NCI-H1437 NFzCVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv5PFhtUUN3ME24MlA6Pzl3IN88US=> NI\kSHhUSU6JRWK=
SNU-449 NHjYSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRThwMkiyO|Ih|ryP NUH3TWMzW0GQR1XS
HCC1187 M3HZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrFemE2UUN3ME24MlI6OzlzIN88US=> MlOxV2FPT0WU
NCI-H2030 M4O4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV64e3REUUN3ME24MlM4PzF2IN88US=> MULTRW5ITVJ?
HuO-3N1 NHHle2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRThwM{e4OFQh|ryP MVjTRW5ITVJ?
COLO-792 NVjz[lZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRThwNEG1Nlch|ryP MofxV2FPT0WU
MIA-PaCa-2 MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDOTWM2OD16Lki1OVA5KM7:TR?= MlHDV2FPT0WU
SK-N-FI MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr0NoFPUUN3ME25MlA1OjVizszN M3TUWXNCVkeHUh?=
MMAC-SF M17xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fJ[2lEPTB;OT6wPVc2OSEQvF2= NGnjUHZUSU6JRWK=
NCI-H28 M{HsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\XcY9KSzVyPUmuNVA1PjlizszN M{jVPHNCVkeHUh?=
ETK-1 MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETmOHhKSzVyPUmuNlk6PzRizszN MkLJV2FPT0WU
NCI-H1993 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTlwNESyOlEh|ryP MmO4V2FPT0WU
no-11 NX\aWpU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfjelRJUUN3ME25MlQ4OTJizszN M2fGUXNCVkeHUh?=
ChaGo-K-1 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fNc2lEPTB;OT61NVU5OyEQvF2= NVvN[nV[W0GQR1XS
NCCIT MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLyXm1KSzVyPUmuOVMyPjlizszN MkHFV2FPT0WU
SAS M2ezUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFyLkK0PEDPxE1? MUHTRW5ITVJ?
A673 NXe3W5IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NViwd|dWUUN3ME2xNE4{PzB2IN88US=> NFXMN4pUSU6JRWK=
NCI-H1522 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFyLkO3NFch|ryP Mn\YV2FPT0WU
NCI-H810 NXfSb2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\hTWM2OD1zMD6zPVA4KM7:TR?= Mnq2V2FPT0WU
IST-MES1 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLNdHJKSzVyPUGwMlQ2PjRizszN M17IZ3NCVkeHUh?=
GR-ST M2KwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DZV2lEPTB;MUCuOVAzPCEQvF2= NH;CUXJUSU6JRWK=
SUP-T1 NVK3[Ws4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7Tcnp[UUN3ME2xNE44OzF5IN88US=> MkPrV2FPT0WU
NB5 NXrEZ4xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXEbGJoUUN3ME2xNE46ODJ{IN88US=> NX7wfndHW0GQR1XS
MZ1-PC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\4TWM2OD1zMD65OVcyKM7:TR?= NUm5VpFRW0GQR1XS
SK-CO-1 NWqyVI83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Xve2lEPTB;MUCuPVk{OSEQvF2= M{PnZnNCVkeHUh?=
Capan-2 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M332dWlEPTB;MUGuN|E6QCEQvF2= MoHmV2FPT0WU
697 NIDRZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLXTWM2OD1zMT62O|U4KM7:TR?= NVz1b2V7W0GQR1XS
REH MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzmXJBKSzVyPUGxMlc1PTFizszN NHLLendUSU6JRWK=
GI-1 NY[1dIVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEixfYFKSzVyPUGxMlg3OTVizszN NF;SNplUSU6JRWK=
BB65-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGx[HVKSzVyPUGyMlA6OTZizszN M4jwU3NCVkeHUh?=
NCI-H1651 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjYTWM2OD1zMj6yOFc5KM7:TR?= MYTTRW5ITVJ?
NCI-H1618 NWm3O4x4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjoPG1KSzVyPUGyMlM6PzZizszN M2j3VnNCVkeHUh?=
NCI-H2081 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF{Lk[xOFEh|ryP MofkV2FPT0WU
GCIY MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF{LkeyNVMh|ryP NEf6fHdUSU6JRWK=
NY NVT6S5M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTzTWM2OD1zMz6wOlQ{KM7:TR?= M3v3e3NCVkeHUh?=
PANC-03-27 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF|LkC4NFch|ryP MWLTRW5ITVJ?
BHY MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF|LkKxNlEh|ryP NVe3UodsW0GQR1XS
SK-OV-3 NVPrZ4h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInuWpZKSzVyPUGzMlM4PjNizszN MmLhV2FPT0WU
5637 M1Lnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF|Lke3OVkh|ryP MorkV2FPT0WU
LC-1F M2LjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF2LkCzOVYh|ryP NVPHZVBIW0GQR1XS
SNB75 NIf4NXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\m[2FMUUN3ME2xOE4xOzh|IN88US=> NX3Sc21yW0GQR1XS
CHP-212 MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\EUWpzUUN3ME2xOE4xPDZ2IN88US=> NYXmWHVFW0GQR1XS
HT-1376 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF2LkGxNlYh|ryP Mo\4V2FPT0WU
MONO-MAC-6 M1j3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\NWng{UUN3ME2xOE4yPTB{IN88US=> MYjTRW5ITVJ?
CA46 MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX0PFJKSzVyPUG0MlE5OjdizszN M{fMZ3NCVkeHUh?=
SCC-15 NHPkTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\T[lZKSzVyPUG0MlU2QDNizszN MVnTRW5ITVJ?
ATN-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF2Lk[2Nlch|ryP M4HUb3NCVkeHUh?=
NCI-H2405 NYfFUHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[1NGFKSzVyPUG0MlgyPTdizszN MmjFV2FPT0WU
NCI-H716 M2TCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHh[JN{UUN3ME2xOE45PDl|IN88US=> MmXSV2FPT0WU
SW620 M3XKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonJTWM2OD1zND65NFE1KM7:TR?= MVLTRW5ITVJ?
NCI-H226 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnuUoxKSzVyPUG0MlkxQDVizszN MoixV2FPT0WU
SW962 M4TpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzZTWM2OD1zND65OFMzKM7:TR?= NHq0RW5USU6JRWK=
KYSE-150 NVXMeWFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnJXplKSzVyPUG0Mlk2PSEQvF2= NEjsWZlUSU6JRWK=
OCUB-M NGT3dGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP1RotKSzVyPUG0Mlk5QDNizszN MVTTRW5ITVJ?
ES7 M13CRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGyR2RKSzVyPUG1MlA6QDRizszN NH75WIpUSU6JRWK=
SW1463 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH2TWM2OD1zNT60NlI{KM7:TR?= M1z1TnNCVkeHUh?=
CAKI-1 NITNVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF3LkWzOFYh|ryP NXKydXVtW0GQR1XS
MKN28 NV\tOnZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP3TFBmUUN3ME2xOU42PDd7IN88US=> NVriVpBZW0GQR1XS
SW13 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PLTWlEPTB;MUWuOlE5KM7:TR?= MYXTRW5ITVJ?
A3-KAW NHrEZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;HTYhKUUN3ME2xOU46Pjl5IN88US=> MYPTRW5ITVJ?
LU-65 MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF3Lkm3Olgh|ryP NHe1V|BUSU6JRWK=
Calu-1 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjLNohKSzVyPUG2MlA{PjhizszN Mn;XV2FPT0WU
ST486 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXxfZhKSzVyPUG2MlA1OzFizszN MXrTRW5ITVJ?
BB30-HNC NUDaT|JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvVTWM2OD1zNj6xNlQ3KM7:TR?= MnzoV2FPT0WU
EGI-1 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjhc2dKSzVyPUG2MlQ1PiEQvF2= NF;CSZpUSU6JRWK=
SH-4 NHvP[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnFRW9KSzVyPUG2MlQ4OzFizszN NWjLXHV{W0GQR1XS
MN-60 MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDnTWM2OD1zNz6yNlk4KM7:TR?= MYrTRW5ITVJ?
MPP-89 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTlcnJ2UUN3ME2xO{4zPDV7IN88US=> M{HLZ3NCVkeHUh?=
A2780 NYW5UWJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVeyV3RjUUN3ME2xO{41OTN7IN88US=> NXnON4xjW0GQR1XS
Daoy Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nuVGlEPTB;MUeuOFY6PSEQvF2= NIjTPVlUSU6JRWK=
NCI-H2126 MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\jTWM2OD1zNz60O|cyKM7:TR?= Mon3V2FPT0WU
NCI-H1563 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPBd2xKSzVyPUG3MlQ6OTdizszN MkjXV2FPT0WU
8-MG-BA Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjMcYJIUUN3ME2xO{43PjR6IN88US=> NWnVOpVJW0GQR1XS
786-0 M1rRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTn[W1OUUN3ME2xO{45OzV|IN88US=> NUHqTXNGW0GQR1XS
AM-38 NYrWZmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW0OFJmUUN3ME2xO{46OzB4IN88US=> MVLTRW5ITVJ?
COLO-824 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTUZoh7UUN3ME2xPE41PDN4IN88US=> M1HSUXNCVkeHUh?=
SK-MEL-30 MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF6LkWwPFIh|ryP MVfTRW5ITVJ?
CESS NFWwVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fRPWlEPTB;MUiuO|YxQSEQvF2= MULTRW5ITVJ?
BL-70 M2W2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e2WmlEPTB;MUiuPFE2PiEQvF2= MYXTRW5ITVJ?
NCI-H2170 MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jn[mlEPTB;MUiuPVE4QSEQvF2= MXLTRW5ITVJ?
HT-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvuPItKSzVyPUG4Mlk5OyEQvF2= MYHTRW5ITVJ?
BOKU NUj0bWhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;kTWM2OD1zOT6wN|gyKM7:TR?= M2LveXNCVkeHUh?=
HPAF-II MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF7LkOwNVUh|ryP M1LzOnNCVkeHUh?=
KGN MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf2c45KSzVyPUG5MlQ4PjVizszN NW\GS2RsW0GQR1XS
MC-CAR MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13lemlEPTB;MUmuOlMyOyEQvF2= NYHXSllDW0GQR1XS
BHT-101 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT5dVg3UUN3ME2xPU44PzdizszN MmKzV2FPT0WU
SW1783 M2jndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF7Lke4NFYh|ryP M1XJfHNCVkeHUh?=
KP-N-YN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnpTWM2OD1{MD6wNlYzKM7:TR?= MX7TRW5ITVJ?
LU-165 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u5dGlEPTB;MkCuOVU4OSEQvF2= NVnCdY5XW0GQR1XS
GOTO Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D6N2lEPTB;MkCuOlQ2OSEQvF2= NF\RT4JUSU6JRWK=
EFM-19 NUiyZ4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJzLkC3NVYh|ryP MXvTRW5ITVJ?
CTV-1 NX3TTZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3xflRKSzVyPUKxMlExPTRizszN M4Hl[nNCVkeHUh?=
HEL M4Pud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJzLkSyNVYh|ryP MlTWV2FPT0WU
SNU-C2B M{P0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\BTWM2OD1{MT60NlYh|ryP MoS5V2FPT0WU
ECC4 NVTmSmx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLpTWM2OD1{MT63NFch|ryP M2W3N3NCVkeHUh?=
NEC8 NHy2XVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17GemlEPTB;MkGuPFM3QCEQvF2= MVPTRW5ITVJ?
KMOE-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJzLki5NlEh|ryP M3PWNHNCVkeHUh?=
NCI-H524 NWSz[W1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPsTWM2OD1{Mj6wPFA5KM7:TR?= NWKz[Yd{W0GQR1XS
WSU-NHL NFX1blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoiyTWM2OD1{Mj6xOVc4KM7:TR?= MkPjV2FPT0WU
SF126 Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj0RXQyUUN3ME2yNk4zPDZ7IN88US=> NW\Yc3BNW0GQR1XS
HOP-92 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfGb25wUUN3ME2yNk4{OTZ5IN88US=> MnPGV2FPT0WU
CTB-1 NX7SVVdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH4WWdnUUN3ME2yNk41Pjd5IN88US=> MoXLV2FPT0WU
KYSE-270 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJ{LkmzOVch|ryP M{j1fHNCVkeHUh?=
SK-MEL-24 M{XXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\KWmlEPTB;MkOuNVg4KM7:TR?= NULpVoVDW0GQR1XS
Calu-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{THZ2lEPTB;MkOuNlEzQCEQvF2= NXnIS2hwW0GQR1XS
GAMG NVOxUphuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32yVGlEPTB;MkOuNlM3PyEQvF2= MVTTRW5ITVJ?
SW1573 NILJdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDiTWM2OD1{Mz63OFE2KM7:TR?= NF3Z[VlUSU6JRWK=
MHH-NB-11 NXS5[XRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zXXmlEPTB;MkSuNFE6PCEQvF2= MWPTRW5ITVJ?
TK10 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL1OXN4UUN3ME2yOE42ODF|IN88US=> M2PoSHNCVkeHUh?=
LB373-MEL-D MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPjeWZKSzVyPUK0MlYxPjRizszN NXHIeJZbW0GQR1XS
KALS-1 NVfqR45DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK2TIRTUUN3ME2yOE44OzJ5IN88US=> M2q1OnNCVkeHUh?=
HUTU-80 NYTpWXRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M365fWlEPTB;MkWuPFA{OiEQvF2= MojoV2FPT0WU
HuP-T3 Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TWb2lEPTB;Mk[uNVY4PCEQvF2= NXvxSGJqW0GQR1XS
OE19 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ4LkKxOVMh|ryP MVHTRW5ITVJ?
J82 M4LPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jRV2lEPTB;Mk[uNlQ4OSEQvF2= NYnoRnJsW0GQR1XS
DU-4475 M3T0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPae2pKSzVyPUK2MlM5OTlizszN MULTRW5ITVJ?
DMS-53 NVHLOGxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\SfFBKSzVyPUK2MlUyOzhizszN MVPTRW5ITVJ?
COLO-741 M1rNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPkW|BKSzVyPUK2Mlg{PDRizszN Mn7WV2FPT0WU
SW48 NFvIPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ4Lki4NkDPxE1? NUnUephLW0GQR1XS
IGR-1 M4fVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;sVXNrUUN3ME2yOk46OzN2IN88US=> MVLTRW5ITVJ?
639-V NWDQWYlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX0OlRKSzVyPUK3MlAzPDVizszN NGXlXXlUSU6JRWK=
LK-2 M{Du[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnRTWM2OD1{Nz60NVQyKM7:TR?= MnXsV2FPT0WU
NCI-H2347 M3jLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\pTWM2OD1{Nz65Olk6KM7:TR?= MnO2V2FPT0WU
NCI-H2228 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTGNIQ5UUN3ME2yPE4xQTB3IN88US=> MVPTRW5ITVJ?
LS-123 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJ6LkGyOlIh|ryP NGezNXhUSU6JRWK=
U031 NH;heYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH5VpRKUUN3ME2yPE4zPTJizszN MYHTRW5ITVJ?
NCI-H1792 NFH6PIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ6LkS3NlEh|ryP MWPTRW5ITVJ?
NCI-H2087 NX:5ZllRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrETWM2OD1{OD63OVUzKM7:TR?= M2jiXXNCVkeHUh?=
NCI-H2342 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ7LkWyNFgh|ryP M13tNHNCVkeHUh?=
SW626 NX7Ob2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ7Lke1OkDPxE1? Mnr0V2FPT0WU
LB2518-MEL M{fNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ7LkixOUDPxE1? NUntdWljW0GQR1XS
RXF393 NIfQdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNyLkC5OVIh|ryP M2KyZnNCVkeHUh?=
LC4-1 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNyLkOwPVIh|ryP NUjCfpFoW0GQR1XS
NCI-H1694 NWS0TINTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNyLk[2NlQh|ryP M4q5[HNCVkeHUh?=
K5 M3qwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\0NYRQUUN3ME2zNE46PzB{IN88US=> NH3GcnVUSU6JRWK=
HDLM-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PyPGlEPTB;M{CuPVczPSEQvF2= NWLIe2xzW0GQR1XS
BCPAP M1q0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXFTWM2OD1|MT64N|c6KM7:TR?= MU\TRW5ITVJ?
BC-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPTVllKSzVyPUOyMlE1ODNizszN NUjvelNUW0GQR1XS
LB996-RCC NXm0U2tST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDPXXl6UUN3ME2zNk4zOzV6IN88US=> NXntfmM3W0GQR1XS
NCI-H2009 NWCyeIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnKe4tpUUN3ME2zNk41QThzIN88US=> Mk\RV2FPT0WU
HTC-C3 M3XpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\2c|hKUUN3ME2zN{44PTF7IN88US=> MV3TRW5ITVJ?
LAMA-84 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLoNWZbUUN3ME2zOE41PDB5IN88US=> MmfUV2FPT0WU
CCRF-CEM M2X2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPMd25VUUN3ME2zOE42PzF3IN88US=> MnruV2FPT0WU
AN3-CA NX7hUYdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13V[2lEPTB;M{WuNFU3QCEQvF2= NX35WIc6W0GQR1XS
NCI-H1734 NVToXnRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnWbJgzUUN3ME2zOU4zPTZzIN88US=> MWPTRW5ITVJ?
Ca-Ski M{PJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\TT4lKSzVyPUO1MlQyODFizszN M1P1bnNCVkeHUh?=
U-266 NUTo[HNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rZcmlEPTB;M{WuOlEyPCEQvF2= M{nGSnNCVkeHUh?=
SBC-5 NHnVWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK3TWM2OD1|NT63O|gyKM7:TR?= NVfUSopTW0GQR1XS
GT3TKB M{SxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrYUmZxUUN3ME2zO{4yOTVizszN NV7sdog4W0GQR1XS
MDA-MB-175-VII NWP0WmhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zjcWlEPTB;M{euNlI1QCEQvF2= MlfhV2FPT0WU
PFSK-1 NF20Uo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P1N2lEPTB;M{euNlQ{PSEQvF2= M2fhW3NCVkeHUh?=
IMR-5 NGfQcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPi[|lbUUN3ME2zO{4zPDh5IN88US=> MUnTRW5ITVJ?
Daudi Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOwSpVJUUN3ME2zO{4{PTl5IN88US=> M3PCUXNCVkeHUh?=
A498 M1n6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnLUpRKSzVyPUO3MlczOThizszN NVfHS3VDW0GQR1XS
SCC-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTQdoU{UUN3ME2zO{44QDR|IN88US=> M4m0XXNCVkeHUh?=
COLO-680N M1zpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnqTWM2OD1|OD6yPFg2KM7:TR?= NX3BRW1IW0GQR1XS
SK-MES-1 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTN6LkOyNVUh|ryP NVXnUFRxW0GQR1XS
SR MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vvTGlEPTB;M{iuOVQ6PSEQvF2= NHS5TpRUSU6JRWK=
LNCaP-Clone-FGC MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTN6LkW2N|ch|ryP NV;wVHR2W0GQR1XS
SK-HEP-1 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN6Lke4NlIh|ryP M4HhU3NCVkeHUh?=
BPH-1 NULuOHhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfi[5hKSzVyPUO4Mlg{OjlizszN M4DoWXNCVkeHUh?=
NCI-H1755 NGjnU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPYTWM2OD1|OT61PFE4KM7:TR?= MlPqV2FPT0WU
LXF-289 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTN7LkiwPFQh|ryP M4XiT3NCVkeHUh?=
SW1088 NVPnenkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRyLkKxNFch|ryP MlXrV2FPT0WU
MOLT-4 NF3ZdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nROWlEPTB;NECuNlkxOSEQvF2= M335WXNCVkeHUh?=
AsPC-1 M{H4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnNVJdZUUN3ME20NE41PTh|IN88US=> MknJV2FPT0WU
HOP-62 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXZRYxKSzVyPUSwMlY2PjhizszN NGS4XotUSU6JRWK=
A172 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD0fmNKSzVyPUSwMlg2OTFizszN M2Xyb3NCVkeHUh?=
SN12C NU[5ZoJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTRyLkmzPFUh|ryP M4[3WXNCVkeHUh?=
MDA-MB-231 NUDKbo5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml75TWM2OD12MD65PFk5KM7:TR?= NFjRcmNUSU6JRWK=
RPMI-2650 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjqe5BKSzVyPUSxMlE2QTNizszN MX\TRW5ITVJ?
KYSE-140 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRzLkixNlMh|ryP NVPBeo9GW0GQR1XS
KINGS-1 NWP3VFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR{LkS2PVch|ryP MXrTRW5ITVJ?
HSC-3 NX35cFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTR{Lk[2OlEh|ryP M3r4VXNCVkeHUh?=
PC-14 NWHjb4xwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPqbZU3UUN3ME20N{4yQDh{IN88US=> NGS4foZUSU6JRWK=
COR-L105 NGnWR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrXe5FKSzVyPUSzMlY2ODJizszN NV3mUWFPW0GQR1XS
BE-13 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\zWXJKSzVyPUS0MlI{PzFizszN NYTFUWhvW0GQR1XS
NCI-H661 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPkbFNKSzVyPUS0MlI6PThizszN NEXQb5RUSU6JRWK=
IST-MEL1 M1nmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULReZhMUUN3ME20OE4{PTl7IN88US=> M2XUU3NCVkeHUh?=
HCC1806 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;hSIZKSzVyPUS0MlU5PzNizszN MUDTRW5ITVJ?
COLO-800 M3HvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTTO4FKSzVyPUS0Mlg1PTNizszN Mn62V2FPT0WU
IST-SL2 NWLqfFlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PWVmlEPTB;NEWuNVI1PyEQvF2= NI\VVoRUSU6JRWK=
8305C MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrSNZBKSzVyPUS1MlMxQSEQvF2= NYPPdmV3W0GQR1XS
UACC-62 NIfJe4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknyTWM2OD12Nj6yPFc2KM7:TR?= NVP2[mhVW0GQR1XS
COR-L23 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTR5LkG5PUDPxE1? NUPMS2xmW0GQR1XS
EFE-184 NGi5[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR5LkO4PEDPxE1? M4fCOHNCVkeHUh?=
DMS-114 NEnPdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r2VWlEPTB;NEeuOFE1QSEQvF2= NU\jWHVYW0GQR1XS
KYSE-520 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjDXnpKSzVyPUS4MlU{OTVizszN NITGfWFUSU6JRWK=
SNG-M M1rJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrTZVY5UUN3ME20PU41OzRizszN MoLvV2FPT0WU
A2058 M3fSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXwdXZKSzVyPUS5MlQ5QDVizszN MkLQV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID